Americans are paying more for prescription drugs than ever before, yet the pharmaceutical industry continues to shirk responsibility, pointing fingers at everyone but itself.
Big Pharma has spent decades perfecting the art of the blame game.
They paint hospitals, insurers, and even government programs as the culprits of high drug prices while quietly raking in record profits at the expense of patients.
Meanwhile, families across the country are forced to choose between life-saving medication and putting food on the table.
The narrative Big Pharma promotes is familiar: they claim that high drug prices are justified by the "immense cost of research and development."
But the numbers tell a different story. The industry spends billions on marketing, advertising, and lobbying each year, dollars that far outstrip what is invested in actual innovation.
Johnson & Johnson spent nearly twice as much on marketing as on research in recent years. Bayer, Pfizer, and many others follow the same pattern.
Meanwhile, the public hears a story of heroic scientists risking everything to bring life-saving treatments to market.
It's a story engineered to distract from a simple truth: profits, not patients, drive the industry.
Big Pharma doesn’t just manipulate public perception; it manipulates policy.
The industry spends hundreds of millions on lobbying annually, funding politicians across the aisle to ensure laws favor corporate bottom lines.
This includes legislation that delays generic drug competition, shields pricing from scrutiny, and undermines efforts to rein in costs for ordinary Americans.
The result is a healthcare system where the most vulnerable are price gouged while the industry’s executives walk away with multimillion-dollar bonuses.
Advertising is another weapon at Big Pharma's disposal.
Direct-to-consumer marketing floods TV screens, social media feeds, and streaming platforms, creating demand for expensive medications, even when cheaper, equally effective alternatives exist.
The money spent on persuasive campaigns dwarfs investments in research and devlopment for breakthrough drugs.
And when independent journalists or watchdog organizations attempt to expose these practices, they are drowned out by an avalanche of public relations, sponsorships, and media buys.
In effect, Big Pharma buys silence, shaping the conversation to protect its profits rather than advancing patient care.
Even when efficiencies that could lower costs are employed, like artificial intelligence in drug discovery or modeling techniques that dramatically reduce development timelines, savings are rarely passed on to patients.
Instead, these efficiencies increase profits of companies that already rank among the most lucrative in the world.
AI can cut development costs by billions and shorten timelines for life-saving drugs, yet Americans continue to pay exorbitant prices, while executives celebrate record earnings and stock buybacks.
High drug prices harm patients, employers, and taxpayers alike.
Medicare and Medicaid spend billions more than they would in a truly competitive market, and out-of-pocket costs leave patients with impossible choices.
Yet Big Pharma persists in its narrative of "uncontrollable costs" and "necessary innovation," carefully omitting the part where profits, marketing, and lobbying dictate every decision.
Congress and regulators have a duty to call out this charade.
It's not enough to tinker at the edges with rebates or incremental reforms.
Policymakers must demand transparency, cap predatory pricing, and ensure that any cost savings from technology or efficiencies are passed directly to patients.
Public health and corporate profits should not exist in opposition, but in today's pharmaceutical market, they do.
Big Pharma can no longer hide behind excuses.
The blame game ends here.
Americans are paying the price of corporate greed, and it's time to demand a healthcare system that values people over profits.
Patients deserve innovation, affordability, and accountability, and they need it now more than ever.
Charlie Kolean has worked as a senior policy adviser for state legislators, multinational corporations, and think tanks. Mr. Kolean has been involved in politics for over a decade as an activist, candidate, political consultant, and party leader. He was a bundler on the Trump Finance Victory Committee, and is a member of the American Association of Political Consultants. Read more of his reports — Here.
© 2025 Newsmax. All rights reserved.